FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582072384> ?p ?o ?g. }

• W2582072384 abstract "Abstract Abstract 397 Background: Although most patients with acute myeloid leukemia (AML) have disease that responds initially to standard cytarabine based induction chemotherapy, approximately 2/3 experience leukemia relapse and succumb to the disease. A reliable and reproducible methodology which could identify individual patients at high risk of disease relapse could be used to selectively triage those patients to more intensive post-remission therapies and thereby improve their outcome while minimizing overall toxicity. Objectives: his study evaluated whether single cell network profiling (SCNP), in which cells are perturbed with a modulator and their response ascertained by multiparametric flow cytometry, could be used to characterize specific signaling network profiles associated with in vivo AML blast chemotherapy resistance. The initial hypothesis was to determine whether: a) intracellular signaling profiles dominant at relapse could be identified in subpopulations of cells present at diagnosis and b) whether the presence of blasts with these intracellular signaling profiles at diagnosis could predict for disease relapse. Methods: Modulated SCNP was evaluated after sample incubation with 14 cytokines (e.g. interleukins and G-CSF), growth factors (e.g. FLT3L, SCF), chemotherapeutic agents (e.g. cytarabine, etoposide), and other modulators. The use of fluorochrome-conjugated antibodies that recognized leukemic blasts and intracellular phospho-epitopes allowed signaling to be measured in specific cell types at the single cell level. In addition, drug transporters and surface receptor levels were measured. Results: Four pairs of AML bone marrow or peripheral blood samples were studied. Intra-patient comparison of intracellular signaling profiles were made between diagnostic samples and with either a primary refractory sample after induction chemotherapy or with a sample obtained at first relapse. High morphologic and functional heterogeneity of myeloblasts was observed in all of the samples both at diagnosis and after induction therapy. Notably, a subpopulation of leukemic cells characterized by simultaneous SCF-mediated increases in the levels of phosphorylated (p-) Akt and p-S6, herein defined as “SCF functional signature”, was identified. This functionally defined leukemic cell subpopulation, although dominant in the post induction samples, was present and detectable at a much lower frequency in the diagnostic samples. Cell surface markers, including c-kit expression, were unable to capture these functionally defined cellular subgroups in single defined subpopulations. The value of the newly identified SCF functional signature in predicting early relapse was then assessed in a larger, independent AML sample set of clinically annotated diagnostic samples. This set included 52 AML samples collected from patients whose leukemia achieved a complete remission after induction chemotherapy, 29 of whom experienced disease relapse within 2 years. In seven of the 52 diagnostic AML samples a subpopulation of blasts displaying the SCF functional signature identified above was detected. Six of these patients experienced disease relapse (five patients within ∼1 year and one patient within 2 years from initial CR). The seventh patient of the group, whose AML blasts carried the t(8;21) translocation (a marker of good prognosis), remained in complete continuous remission at 2 years. Noteworthy, the prognostic value of the SCF functional signature was independent of FLT3 mutational status: of the five patients who relapsed in only one case the leukemic blasts carried the FLT3 ITD mutation. Conclusions SCNP offers a novel approach to identify subpopulations of cells present at diagnosis with characteristics predictive of higher rates of relapse and this information can be used for monitoring or to guide therapy. Disclosures: Cesano: Nodality, Inc.: Employment, Equity Ownership. Woronicz:Nodality, Inc.: Employment, Equity Ownership. Cleary Cohen:Nodality Inc.: Employment, Equity Ownership. Covey:Nodality, Inc.: Employment, Equity Ownership. Putta:Nodality, Inc.: Employment, Equity Ownership. Gayko:Nodality, Inc.: Employment, Equity Ownership. Fantl:Nodality, Inc.: Employment, Equity Ownership. Kornblau:Nodality, Inc.: Consultancy." @default.
• W2582072384 created "2017-02-03" @default.
• W2582072384 creator A5009460287 @default.
• W2582072384 creator A5016607292 @default.
• W2582072384 creator A5050588157 @default.
• W2582072384 creator A5051654875 @default.
• W2582072384 creator A5053257332 @default.
• W2582072384 creator A5053316156 @default.
• W2582072384 creator A5064221788 @default.
• W2582072384 creator A5071972147 @default.
• W2582072384 date "2009-11-20" @default.
• W2582072384 modified "2023-10-01" @default.
• W2582072384 title "Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure." @default.
• W2582072384 doi "https://doi.org/10.1182/blood.v114.22.397.397" @default.
• W2582072384 hasPublicationYear "2009" @default.
• W2582072384 type Work @default.
• W2582072384 sameAs 2582072384 @default.
• W2582072384 citedByCount "0" @default.
• W2582072384 crossrefType "journal-article" @default.
• W2582072384 hasAuthorship W2582072384A5009460287 @default.
• W2582072384 hasAuthorship W2582072384A5016607292 @default.
• W2582072384 hasAuthorship W2582072384A5050588157 @default.
• W2582072384 hasAuthorship W2582072384A5051654875 @default.
• W2582072384 hasAuthorship W2582072384A5053257332 @default.
• W2582072384 hasAuthorship W2582072384A5053316156 @default.
• W2582072384 hasAuthorship W2582072384A5064221788 @default.
• W2582072384 hasAuthorship W2582072384A5071972147 @default.
• W2582072384 hasConcept C126322002 @default.
• W2582072384 hasConcept C143998085 @default.
• W2582072384 hasConcept C150903083 @default.
• W2582072384 hasConcept C203014093 @default.
• W2582072384 hasConcept C207001950 @default.
• W2582072384 hasConcept C2776694085 @default.
• W2582072384 hasConcept C2778041864 @default.
• W2582072384 hasConcept C2778119113 @default.
• W2582072384 hasConcept C2778461978 @default.
• W2582072384 hasConcept C2778729363 @default.
• W2582072384 hasConcept C2780007613 @default.
• W2582072384 hasConcept C502942594 @default.
• W2582072384 hasConcept C71924100 @default.
• W2582072384 hasConcept C86803240 @default.
• W2582072384 hasConcept C98274493 @default.
• W2582072384 hasConceptScore W2582072384C126322002 @default.
• W2582072384 hasConceptScore W2582072384C143998085 @default.
• W2582072384 hasConceptScore W2582072384C150903083 @default.
• W2582072384 hasConceptScore W2582072384C203014093 @default.
• W2582072384 hasConceptScore W2582072384C207001950 @default.
• W2582072384 hasConceptScore W2582072384C2776694085 @default.
• W2582072384 hasConceptScore W2582072384C2778041864 @default.
• W2582072384 hasConceptScore W2582072384C2778119113 @default.
• W2582072384 hasConceptScore W2582072384C2778461978 @default.
• W2582072384 hasConceptScore W2582072384C2778729363 @default.
• W2582072384 hasConceptScore W2582072384C2780007613 @default.
• W2582072384 hasConceptScore W2582072384C502942594 @default.
• W2582072384 hasConceptScore W2582072384C71924100 @default.
• W2582072384 hasConceptScore W2582072384C86803240 @default.
• W2582072384 hasConceptScore W2582072384C98274493 @default.
• W2582072384 hasLocation W25820723841 @default.
• W2582072384 hasOpenAccess W2582072384 @default.
• W2582072384 hasPrimaryLocation W25820723841 @default.
• W2582072384 hasRelatedWork W1554744388 @default.
• W2582072384 hasRelatedWork W2024920564 @default.
• W2582072384 hasRelatedWork W2031261478 @default.
• W2582072384 hasRelatedWork W2050400868 @default.
• W2582072384 hasRelatedWork W2079340697 @default.
• W2582072384 hasRelatedWork W2123798150 @default.
• W2582072384 hasRelatedWork W2185768918 @default.
• W2582072384 hasRelatedWork W2240890818 @default.
• W2582072384 hasRelatedWork W2300582939 @default.
• W2582072384 hasRelatedWork W2398746772 @default.
• W2582072384 hasRelatedWork W2570345866 @default.
• W2582072384 hasRelatedWork W2574604524 @default.
• W2582072384 hasRelatedWork W2582224676 @default.
• W2582072384 hasRelatedWork W2584439205 @default.
• W2582072384 hasRelatedWork W2591403031 @default.
• W2582072384 hasRelatedWork W2595888193 @default.
• W2582072384 hasRelatedWork W2749521159 @default.
• W2582072384 hasRelatedWork W2953541346 @default.
• W2582072384 hasRelatedWork W3196730579 @default.
• W2582072384 hasRelatedWork W2741697000 @default.
• W2582072384 isParatext "false" @default.
• W2582072384 isRetracted "false" @default.
• W2582072384 magId "2582072384" @default.
• W2582072384 workType "article" @default.